AGA
MRNA icon

Accuvest Global Advisors’s Moderna MRNA Stock Holding History

Accuvest Global Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,988
Closed -$242K – 122
2023
Q2 		$242K Buy
1,988
+287
+17% +$38.3K 0.12% 112
2023
Q1 		$261K Sell
1,701
-1,701
-50% -$281K 0.12% 118
2022
Q4 		$611K Buy
3,402
+1,299
+62% +$212K 0.2% 82
2022
Q3 		$249K Sell
2,103
-683
-25% -$104K 0.17% 80
2022
Q2 		$398K Sell
2,786
-89
-3% -$12.7K 0.26% 69
2022
Q1 		$495K Buy
2,875
+1,438
+100% +$242K 0.25% 69
2021
Q4 		$365K Buy
+1,437
New +$420K 0.16% 81

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Accuvest Global Advisors's MRNA Position: Q3 2023 in Review

Accuvest Global Advisors sold out of Moderna (MRNA) in Q3 2023, closing a stake of 1,988 shares — an estimated $242K sold.

Accuvest Global Advisors first reported a position in MRNA in Q4 2021 and held it in 7 quarters. The position peaked at $611K in Q4 2022. 889 funds tracked by Wall St. Rank hold MRNA as of Q3 2023.

  • Accuvest Global Advisors reported no remaining Moderna position as of Q3 2023 after selling out during the quarter.
  • Accuvest Global Advisors sold 1,988 Moderna shares in Q3 2023, an estimated $242K.
  • Accuvest Global Advisors first reported a position in Moderna in Q4 2021 and held it in 7 quarters.
  • Accuvest Global Advisors's Moderna position peaked at $611K in Q4 2022.
  • 889 funds tracked by Wall St. Rank held Moderna as of Q3 2023.

Based on Accuvest Global Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.